Back to the portfolio

Porcine Circovirus Type 2 causes Postweaning Multisystemic Wasting Syndrome (PMWS)

Biotech & TherapeuticsAgriculture & FoodLab validated

This technology is a genetically engineered vaccine for pigs that targets Porcine Circovirus Type 2 (PCV2), a virus that causes wasting syndrome in livestock. Scientists created a hybrid virus by taking a harmless version of the virus (PCV1) and swapping in a specific gene from the harmful version (PCV2). This allows the pig's immune system to learn to recognize and fight the dangerous virus without the pig actually getting sick from the vaccine itself.

What you could build

A live-attenuated viral vaccine for swine sold to large-scale pork producers and veterinary pharmaceutical companies to prevent PMWS outbreaks. The product would be administered to young piglets to ensure herd immunity and reduce livestock mortality.

Who in Virginia should care

Virginia has a significant swine production industry, and this technology directly supports the health and profitability of local livestock operations and veterinary research hubs like the Virginia-Maryland College of Veterinary Medicine.

Readiness: Lab validated

Concept, described but not yet demonstrated. Lab validated, supported by experimental results in the patent. Prototype likely, the text describes a built, working embodiment.

Readiness is inferred from the patent text, not from a lab visit.

The record

Inventors
Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
Granted
November 15, 2011
Status
Granted patent
Patent number
8058048

Ready to talk?

the university handles licensing for this technology. Email us for an introduction patents@harbor.capital.

Sonar summaries are generated from public patent text and are not legal advice.